Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

The median bone metastasis–free survival among men with nonmetastatic, castration-resistant prostate cancer ranges from 25 to 30 months. The risk of metastases is associated with an increasing prostate-specific antigen (PSA) level and a PSA doubling time (the estimated time required for the PSA…

https://ift.tt/2MA2GB4

Metastasis-free Survival — A New End Point in Prostate Cancer Trials

Earlier this year, the Food and Drug Administration (FDA) approved apalutamide, an androgen receptor inhibitor, for treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). The approval was based on SPARTAN, a randomized, placebo-controlled trial involving 1207…

https://ift.tt/2KzdL83

Progress in Nonmetastatic Prostate Cancer

Since 2010, the Food and Drug Administration (FDA) has approved five new drugs for the treatment of metastatic, castration-resistant prostate cancer on the basis of a primary end point of overall survival. Progress in the treatment of nonmetastatic prostate cancer has been slower. A series of phase…

https://ift.tt/2MBwSvD

Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss

Hepatoblastoma is a rare primary liver cancer with an age-adjusted incidence of 0.13 patients per 100,000 population. Hepatoblastoma can be categorized as standard-risk or high-risk disease according to the serum alpha-fetoprotein level in addition to the results of the revised Pretreatment Extent…

https://ift.tt/2KAVcjO

Inhaled Corticosteroids and LABAs — Removal of the FDA’s Boxed Warning

For years, the risks associated with the use of long-acting beta-agonists (LABAs) in patients with asthma have been uncertain, and some health care professionals have recommended conducting large clinical trials to gather important safety information on these products. In December 2017, the Food…

https://ift.tt/2KBaphK

Metastasis-free Survival — A New End Point in Prostate Cancer Trials

Earlier this year, the Food and Drug Administration (FDA) approved apalutamide, an androgen receptor inhibitor, for treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). The approval was based on SPARTAN, a randomized, placebo-controlled trial involving 1207…

https://ift.tt/2KzdL83

Making Neighborhood-Disadvantage Metrics Accessible — The Neighborhood Atlas

Health disparities are a major problem in the United States: many conditions, including cardiovascular disease, diabetes, and Alzheimer's disease, disproportionately affect racial and ethnic minorities and the socioeconomically disadvantaged. Few interventions have successfully reduced these…

https://ift.tt/2tUTfo2